Patient Perception Study for AL-4943A

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01294969

Enrollment

Registered

2011-02-14

Start date

2010-09-30

Completion date

2011-10-31

Last updated

2016-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Keywords

Allergic conjunctivitis

Brief summary

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Interventions

DRUGAL-4943A

Once daily topical ocular allergy medication used for 7 days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* History of allergic conjunctivitis within last 24 months * Active signs and symptoms of ocular allergies

Exclusion criteria

* Severe or serious ocular condition, ocular surgical intervention, ocular infection

Design outcomes

Primary

Measure	Time frame
Overall Patient satisfaction	7 days

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026